LEAP THERAPEUTICS, INC.

(LPTX)
  Report
Delayed Nasdaq  -  05/13 04:00:00 pm EDT
1.310 USD   +34.58%
05/13LEAP THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
05/13Leap Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
03/11LEAP THERAPEUTICS : Reports Fourth Quarter and Full Year 2021 Financial Results - Form 8-K
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Leap Therapeutics Shares Rise Premarket on Encouraging Study Data

01/19/2022 | 07:02am EDT

By Colin Kellaher


Shares of Leap Therapeutics Inc. rose more than 10% in premarket trading Wednesday after the biotechnology company reported positive data from a Phase 2a study of DKN-01, its most advanced clinical candidate, in combination with BeiGene Ltd.'s tislelizumab.

The Cambridge, Mass., company said the combination showed encouraging clinical activity in both first- and second-line advanced gastric or gastroesophageal junction cancer patients.

Leap is conducting the study as part of an exclusive option and license agreement with BeiGene for the development of DKN-01 in Asia (excluding Japan), Australia and New Zealand.

Leap shares, which closed Tuesday at $2.72, were recently up 11.4% to $3.03 in premarket trading.


Write to Colin Kellaher at colin.kellaher@wsj.com


(END) Dow Jones Newswires

01-19-22 0702ET

Stocks mentioned in the article
ChangeLast1st jan.
BEIGENE, LTD. 1.06% 132.87 Delayed Quote.-50.96%
LEAP THERAPEUTICS, INC. 34.58% 1.31 Delayed Quote.-59.57%
ON SEMICONDUCTOR CORPORATION 6.04% 56.18 Delayed Quote.-17.29%
All news about LEAP THERAPEUTICS, INC.
05/13LEAP THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition an..
AQ
05/13Leap Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, ..
CI
03/11LEAP THERAPEUTICS : Reports Fourth Quarter and Full Year 2021 Financial Results - Form 8-K
PU
03/11LEAP THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition an..
AQ
03/11Leap Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2..
CI
03/02Leap Therapeutics to Present at Raymond James 43rd Annual Institutional Investors Confe..
PR
01/31Leap Therapeutics, Leica Team Up to Develop Companion Diagnostic for Cancer Patients
MT
01/31Leica Biosystems and Leap Therapeutics Partner on Companion Diagnostic to Advance Care ..
CI
01/24Leap Therapeutics to Present at B. Riley Securities Oncology Investor Conference
PR
01/24Piper Sandler Adjusts Leap Therapeutics' Price Target to $6 From $5, Reiterates Overwei..
MT
More news
Analyst Recommendations on LEAP THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -46,8 M - -
Net Debt 2022 - - -
P/E ratio 2022 -3,21x
Yield 2022 -
Capitalization 116 M 116 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 50,3x
Nbr of Employees 36
Free-Float 80,0%
Chart LEAP THERAPEUTICS, INC.
Duration : Period :
Leap Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LEAP THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 1,31 $
Average target price 5,00 $
Spread / Average Target 282%
EPS Revisions
Managers and Directors
Doug E. Onsi President, CEO, CFO, Secretary & Treasurer
Chris K. Mirabelli Chairman
Cynthia Sirard Chief Medical Officer
Michael Haas Head-Research
Augustine J. Lawlor Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
LEAP THERAPEUTICS, INC.-59.57%116
GILEAD SCIENCES, INC.-14.10%78 232
REGENERON PHARMACEUTICALS, INC.2.22%69 552
VERTEX PHARMACEUTICALS12.35%63 100
WUXI APPTEC CO., LTD.-14.92%43 023
BIONTECH SE-38.39%38 601